OpenAI researcher Miles Wang is in talks to launch a new startup focused on AI-powered drug discovery, with a valuation of $2 billion, according to sources familiar with the matter.
The discussions highlight growing investor interest in applying artificial intelligence to make breakthroughs in life sciences, particularly in drug development.
Lightspeed in talks to lead the funding round
According to TechCrunch, venture capital firm Lightspeed is in discussions to lead the funding round for the new venture. The exact terms of the deal have not been finalized, but the startup is already being valued at $2 billion.
The involvement of a top-tier investor like Lightspeed signals strong confidence in Wang's vision and the potential of AI-driven drug discovery.
What this means for AI in life sciences
The news comes at a time when AI is increasingly being used to accelerate drug development, from identifying new drug candidates to predicting clinical trial outcomes. Wang's move from OpenAI — a leader in artificial general intelligence — to a biotech-focused startup reflects a broader trend of AI talent moving into the healthcare and life sciences sectors.
While the startup is still in its early stages, the $2 billion valuation suggests that investors believe AI can significantly reduce the time and cost of bringing new drugs to market.
Our Take: A sign of AI's growing role in healthcare
In our view, this development is a clear signal that the intersection of AI and drug discovery is becoming a major focus for investors. The $2 billion valuation — before the company has even launched — shows just how much faith the market has in AI's ability to transform the pharmaceutical industry.
However, it is important to remember that drug discovery is a long and risky process. Many AI-driven biotech startups have raised large sums but struggled to deliver real-world results. Wang's background at OpenAI gives the venture credibility, but the real test will be whether the technology can actually produce new, effective drugs.
For now, this is a story worth watching — both for what it says about the future of AI and for what it means for patients who could benefit from faster drug development.
